Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telavancin positive Phase III data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Theravance announces positive results from its pivotal Phase III ATLAS I and ATLAS II trials to assess the safety and efficacy of telavancin, an injectable lipoglycopeptide antibiotic for treatment of complicated skin and skin structure infections. The multi-center, multinational, double-blind studies enrolled 1,867 patients, 719 of whom were infected with methicillin-resistant Staphylococcus aureus. Both studies reached their primary endpoints of non-inferiority and achieved a numerically better clinical cure rate than vancomycin. The company announced Phase II results at the Interscience Conference on Antimicrobial Agents and Chemotherapy last December 1(Pharmaceutical Approvals Monthly January 2006, p. 36)...
Advertisement

Related Content

ICAAC In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS003408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel